AZD1208 hydrochloride is primarily investigated for its potential in cancer therapy, particularly in targeting hematologic malignancies and solid tumors. It functions as a potent and selective inhibitor of Pim kinases, which are often overexpressed in various cancers and contribute to tumor growth and survival. By inhibiting these kinases, it aims to disrupt signaling pathways that promote cancer cell proliferation and resistance to apoptosis. This compound has shown promise in preclinical studies for its ability to enhance the efficacy of other cancer treatments, such as chemotherapy and targeted therapies. Research is ongoing to explore its therapeutic potential in combination regimens and its role in overcoming drug resistance in cancer cells.